JPH07135923A - Composition for functional food - Google Patents

Composition for functional food

Info

Publication number
JPH07135923A
JPH07135923A JP5314499A JP31449993A JPH07135923A JP H07135923 A JPH07135923 A JP H07135923A JP 5314499 A JP5314499 A JP 5314499A JP 31449993 A JP31449993 A JP 31449993A JP H07135923 A JPH07135923 A JP H07135923A
Authority
JP
Japan
Prior art keywords
licorice
functional food
extract
lactic acid
chitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5314499A
Other languages
Japanese (ja)
Inventor
Takeo Tanabe
武男 田辺
Satoshi Ihara
郷司 井原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP5314499A priority Critical patent/JPH07135923A/en
Publication of JPH07135923A publication Critical patent/JPH07135923A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To provide a composition for functional food further improved in the pharmacological activity such as hepatopathy protecting activity of the licorice extract contained therein, thus having health protecting effect and health therapeutic effect even on hepatitis C. CONSTITUTION:The objective composition for functional foods formulated with (A) chitin and/or chitosan as well as (B) at least one kind selected from the extracts from licorice and the lactic fermentation products of said extracts.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本願発明は、機能性食品用組成
物、さらに詳しくは肝臓疾患の治療及び予防に有効であ
ると言われる甘草属植物から得られる抽出物を含有し、
さらにその機能を高めた機能性食品用組成物に関するも
のである。
FIELD OF THE INVENTION The present invention contains a composition for functional foods, more specifically an extract obtained from a licorice plant which is said to be effective for the treatment and prevention of liver diseases.
The present invention also relates to a functional food composition having improved functions.

【0002】[0002]

【従来の技術】肝臓疾患の治療方法としては、安静療
法、食事療法、薬物療法等が知られている。これらの療
法の内、薬物療法としては、アスパラギン酸、チオクト
酸等のアミノ酸、肝臓抽出エキス、肝臓水解物、胎盤水
解物、グルクロン酸誘導体及び甘草から抽出したグリチ
ルリチン等を使用する方法が知られている。また、特開
平1−104010号では甘草の抽出物中のイソリクイ
リチゲニンまたはその薬学的に許容される塩を有効成分
とする腎臓及び肝臓疾患の治療及び予防用薬剤の提案も
なされている。さらに、国際特許公開WO92/139
3においては、甘草属植物から得られる抽出物を乳酸醗
酵させることにより、肝障害保護作用等の保健予防効果
及び保健治療効果を維持増強させつつ食し易くした機能
性食品用組成物の提案がなされ、実用化されているが、
C型肝炎に関しては、未だ満足のいく結果を得ることが
できないのが現状であり、さらなる改良が望まれてい
る。
2. Description of the Related Art Restoration therapy, diet therapy, drug therapy and the like are known as methods for treating liver diseases. Among these therapies, as drug therapy, a method using aspartic acid, amino acids such as thioctic acid, liver extract, liver hydrolyzate, placenta hydrolyzate, glucuronic acid derivative and glycyrrhizin extracted from licorice is known. There is. Further, JP-A-1-104010 proposes a drug for treating and preventing kidney and liver diseases, which comprises isoliquiritigenin or a pharmaceutically acceptable salt thereof in an extract of licorice as an active ingredient. . Further, International Patent Publication WO92 / 139
In 3, there is proposed a functional food composition that is easy to eat while maintaining and enhancing health preventive effects such as liver damage protecting effect and health therapeutic effects by lactic acid fermentation of an extract obtained from a licorice plant. Has been put to practical use,
With regard to hepatitis C, it is the current situation that satisfactory results cannot be obtained yet, and further improvement is desired.

【0003】[0003]

【発明が解決しようとする課題】本願発明は、甘草の抽
出物の肝障害保護作用等の薬理作用をさらに向上させ、
C型肝炎に関しても保健予防効果及び保健治療効果を発
揮することのできる機能性食品用組成物を提供せんとす
るものである。
DISCLOSURE OF THE INVENTION The present invention further improves the pharmacological action of licorice extract such as the action for protecting liver damage,
It is intended to provide a functional food composition capable of exerting a health preventive effect and a health therapeutic effect for hepatitis C.

【0004】[0004]

【課題を解決するための手段】しかして、本願発明者は
鋭意研究の結果、甘草属植物から得られる抽出物と甘草
属植物から得られる抽出物の乳酸醗酵物とから選択され
る少なくとも一種に加えて、キチンとキトサンとから選
択される少なくとも一種を配合することにより、C型肝
炎に関しても充分な保健予防効果及び保健治療効果を発
揮することを知見して本願発明の完成に到ったものであ
る。
DISCLOSURE OF THE INVENTION However, as a result of earnest research, the inventors of the present invention have found that at least one selected from an extract obtained from a licorice plant and a lactic acid fermentation product of an extract obtained from a licorice plant. In addition, the inventors have found that the compounding of at least one selected from chitin and chitosan exerts sufficient health preventive effect and health therapeutic effect on hepatitis C, and has completed the invention of the present application. Is.

【0005】本願発明に係る甘草属植物としては、従来
より漢方薬として用いられている甘草を用いることがで
き、例えば、満州甘草、光果甘草、スペイン甘草、ロシ
ア甘草、ペルシア甘草等を挙げることができる。
As the licorice plant according to the present invention, licorice conventionally used as a herbal medicine can be used, and examples thereof include Manchurian licorice, light fruit licorice, Spanish licorice, Russian licorice and Persia licorice. it can.

【0006】この甘草の抽出方法は、従来の方法と同様
でよく、より具体的には、甘草に重量比で1〜1000
倍の水を加え、必要に応じて加熱して、1〜72時間抽
出処理すればよい。抽出物としては、この抽出処理によ
り得られた液をそのまま抽出物として使用することもで
き、或いは、この抽出液に対して水分の除去処理を施し
たものを使用することもできる。抽出に使用する甘草
は、乾燥物や乾燥物を粉状になしたものを利用すればよ
いが、乾燥処理を施さなくともよい。使用する部位は、
甘草全体であってもよく、或いは、根や茎(ストロン)
等の一部であってもよく、特に、皮を除去した根の乾燥
物や皮を除去した茎(ストロン)の乾燥物が好適であ
る。また、甘草抽出物として従来より漢方薬に使用され
ている甘草エキスを用いることもでき、これを水にて希
釈したり、或いは、甘草粗エキスを水に懸濁した液を用
いてもよい。本願発明においては、これらの液、或い
は、当該甘草エキス、甘草粗エキス自体も甘草抽出物と
いう。
The method for extracting licorice may be the same as the conventional method, and more specifically, the licorice may be extracted in a weight ratio of 1 to 1000.
Double the amount of water may be added, and the mixture may be heated if necessary and subjected to extraction treatment for 1 to 72 hours. As the extract, the liquid obtained by this extraction treatment can be used as it is as an extract, or the extract obtained by subjecting this extract to a water removal treatment can be used. The licorice used for extraction may be a dried product or a powdered product of the dried product, but may not be dried. The part used is
Can be whole licorice, or roots and stems (Strong)
Etc. may be a part thereof, and in particular, a dried product of roots from which skins have been removed and a dried product of stems (Strong) from which skins have been removed are preferable. Further, as the licorice extract, a licorice extract conventionally used in Chinese herbs can be used, and this may be diluted with water, or a liquid obtained by suspending the crude licorice extract in water may be used. In the present invention, these liquids, or the licorice extract and crude licorice extract themselves are also referred to as licorice extract.

【0007】この甘草抽出物は、そのまま配合してもよ
いが、乳酸醗酵処理を施してもよい。乳酸醗酵処理を行
う場合には、液状の甘草抽出物、即ち、上記の甘草に抽
出処理を施して得た抽出液や甘草エキス或いは甘草粗エ
キスから製造した液を用いることが好ましい。この液状
の甘草抽出物を乳酸醗酵させるには、従来周知の乳製品
を得るために用いられている各種の乳酸菌を単独で或い
は併用して用いることができる。また、乳酸醗酵して得
られた乳製品、例えばヨーグルトに含まれている乳酸菌
を、この乳製品と共に使用してもよい。乳酸醗酵の条件
は、使用する乳酸菌の種類に応じて醗酵に適した環境を
整えてやればよく、通常、1日以上、低温(1〜4°
C)状態で静置する。また必要に応じて、寒天等に乳酸
菌に対する栄養源を混在させてもよい。この乳酸醗酵
は、乳酸液中に含まれるイソリクイリチン(甘草由来の
成分)1重量部に対して、乳酸(乳酸菌の代謝生産物)
16〜500重量部、グリチルリチン(甘草由来の成
分)1/3〜30重量部となるように行うことが、味覚
の点で好ましい。この液状の甘草抽出物を乳酸醗酵させ
ることにより、液状の乳酸醗酵物が得られ、これはその
まま、甘草属植物から得られる抽出物の乳酸醗酵物とし
て用いることができる。また、この液状の乳酸醗酵物に
対して、滅菌処理を施したり、不溶物を遠心分離等によ
り除去したものを用いることができ、これらの液を濃縮
したものを用いてもよい。さらに、これらの液から、水
分を除去し、半固形或いは固形のものとして用いること
もできる。
The licorice extract may be blended as it is, or may be subjected to a lactic acid fermentation treatment. When performing lactic acid fermentation treatment, it is preferable to use a liquid licorice extract, that is, an extract obtained by subjecting the above licorice to an extraction treatment, or a liquid produced from a licorice extract or a crude licorice extract. In order to ferment this liquid licorice extract into lactic acid, various lactic acid bacteria used for obtaining conventionally known dairy products can be used alone or in combination. A dairy product obtained by lactic acid fermentation, for example, lactic acid bacteria contained in yogurt may be used together with this dairy product. The conditions for lactic acid fermentation may be such that an environment suitable for fermentation is prepared according to the type of lactic acid bacteria used, and usually one day or more, low temperature (1 to 4 ° C).
C) Leave still. If necessary, a nutrient source for lactic acid bacteria may be mixed in agar or the like. This lactic acid fermentation is based on 1 part by weight of isoliquiritin (a component derived from licorice) contained in the lactic acid solution and lactic acid (a metabolic product of lactic acid bacteria).
From the viewpoint of taste, it is preferable that the amount of glycyrrhizin (a component derived from licorice) is 1/3 to 30 parts by weight. The liquid licorice extract is subjected to lactic acid fermentation to obtain a liquid lactic acid fermentation product, which can be used as it is as a lactic acid fermentation product of an extract obtained from a licorice plant. The liquid lactic acid fermentation product may be sterilized or the insoluble matter may be removed by centrifugation or the like, and a concentrated product of these liquids may be used. Further, water can be removed from these liquids and used as a semi-solid or solid product.

【0008】次に、キチン及びキトサンは、カニやエビ
等の甲殻類の殻、昆虫の表皮、イカや貝等の軟体動物の
器官、キノコ等の菌類の細胞壁等々自然界に広く存在す
るキチン質から得られる。一般には、カニやエビ等の甲
殻類の殻を希アルカリ溶液に浸漬して蛋白質を除去し、
次いで、希酸溶液に浸漬して炭酸カルシウムを除去する
ことにより、キチンが得られる。キトサンは、キチン
を、濃アルカリ溶液中で80〜120°C、4〜5時間
熱処理を施すことにより、N−アセチル基が脱落して生
成されるものである。また、キチンは、キチンオリゴ糖
として用いることもできる。このキチン及びキトサン
は、甲殻類の殻等に含まれ、血中コレステロールの降
下、心臓病の予防、肝臓疾患予防作用等々があると言わ
れており、特に、低分子オリゴ糖は、抗菌性(抗癌作
用)、免疫力強化作用が見出されて注目されている。
[0008] Next, chitin and chitosan are derived from chitin widely existing in nature such as shells of crustaceans such as crab and shrimp, epidermis of insects, organs of molluscs such as squid and shellfish, cell walls of fungi such as mushrooms. can get. Generally, the shells of crustaceans such as crabs and shrimps are immersed in a dilute alkaline solution to remove proteins,
Then, it is dipped in a dilute acid solution to remove calcium carbonate, whereby chitin is obtained. Chitosan is produced by subjecting chitin to heat treatment in a concentrated alkaline solution at 80 to 120 ° C. for 4 to 5 hours to remove N-acetyl groups. Chitin can also be used as a chitin oligosaccharide. This chitin and chitosan are contained in shells of crustaceans and the like, and are said to have blood cholesterol lowering, heart disease prevention, liver disease prevention actions, etc. In particular, low molecular oligosaccharides have antibacterial properties ( An anti-cancer effect) and an immunity enhancing effect have been found and attracted attention.

【0009】本願発明の機能性食品組成物は、上記の甘
草属植物から得られる抽出物或いは甘草属植物から得ら
れる抽出物の乳酸醗酵物に、キチン及び/又はキトサン
を配合してなるものであり、液状、半固形、固形等の状
態で供給することができ、ドリンク、ゼリー、焼き菓子
等の従来周知の食品の形状を採ることもできる。またそ
の際、澱粉、蛋白質、ビタミンC等のビタミン、大豆レ
シチン、ベータカロチン、大豆油、サフラワー油、クロ
レラ、ニンニクエキス、ゼラチン、ミツロウ、シイタケ
エキス、マムシ抽出エキス、果糖、ブドウ糖、塩化ナト
リウム、乳酸カルシウム、炭酸カルシウム、L−グルタ
ミン酸ナトリウム等々、食用可能な物質と配合すること
が可能である。
The functional food composition of the present invention comprises the above-mentioned extract obtained from a licorice plant or a lactic acid fermentation product of an extract obtained from a licorice plant and chitin and / or chitosan. It can be supplied in a liquid state, a semi-solid state, a solid state, or the like, and can take the form of conventionally known foods such as drinks, jellies, and baked confectioneries. At that time, starch, protein, vitamins such as vitamin C, soybean lecithin, beta carotene, soybean oil, safflower oil, chlorella, garlic extract, gelatin, beeswax, shiitake extract, viper extract, fructose, glucose, sodium chloride, It is possible to mix with edible substances such as calcium lactate, calcium carbonate, sodium L-glutamate and the like.

【0010】[0010]

【実施例】次に、本願発明の理解を高めるために、本願
発明に係る機能性食品用組成物による機能性食品の実施
例を示す。まず、甘草属植物から得られる抽出物或いは
甘草属植物から得られる抽出物の乳酸醗酵物として株式
会社日本ハイポックスより市販されているネオカンゴー
ルド(以下、機能性食品1という)に対して、キチン及
び/又はキトサンとして亜細亜製薬株式会社のカニトッ
プハイゴールド(以下、機能性食品2という)を配合し
て、実施例1に係る機能性食品を得た。機能性食品1
は、1本50mlのドリンクとして市販されており、その
成分は、甘草エキス、赤まむし抽出エキス、果糖、ブド
ウ糖、液糖、ビタミンC、塩化ナトリウム、乳酸カルシ
ウム、炭酸ナトリウム、L−グルタミン酸ナトリウム、
カフェイン、香料である。機能性食品2は、ペースト状
体をカプセル内に封入したものであり、その成分はキト
サン90mg、キチンオリゴ糖3mg、大豆レシチン6.4
mg、ベーターカロチン5mg、大豆油40mg、無臭ニンニ
ク3.6mg、ゼラチン320mg、サフラワー油164m
g、ポエムS4mg、ミツロウ4mgである。配合に際して
は、機能性食品2のカプセル内よりペースト状体のみを
取り出して機能性食品1に配合して攪拌した。配合比率
は、1本の機能性食品1に対して、機能性食品2を5〜
30錠とした。
EXAMPLES Next, in order to enhance understanding of the present invention, examples of functional foods using the functional food composition according to the present invention will be shown. First, against the neo-can gold (hereinafter referred to as functional food 1) marketed by Nippon Hypox Co., Ltd. as a lactic acid fermentation product of an extract obtained from a licorice plant or an extract obtained from a licorice plant, chitin And / or chitosan was mixed with Crab Top High Gold of Asia Pharmaceutical Co., Ltd. (hereinafter referred to as functional food 2) to obtain the functional food according to Example 1. Functional food 1
Is sold as a 50 ml drink, and its ingredients are licorice extract, red bean extract, fructose, glucose, liquid sugar, vitamin C, sodium chloride, calcium lactate, sodium carbonate, sodium L-glutamate,
Caffeine and fragrance. The functional food 2 is a paste-like substance enclosed in a capsule, and the components thereof are 90 mg of chitosan, 3 mg of chitin oligosaccharide, and soybean lecithin 6.4.
mg, beta-carotene 5 mg, soybean oil 40 mg, odorless garlic 3.6 mg, gelatin 320 mg, safflower oil 164 m
g, Poem S 4 mg, beeswax 4 mg. At the time of blending, only the paste-like material was taken out from the capsule of the functional food 2, blended with the functional food 1, and stirred. The mixing ratio is such that 1 functional food 1 to 5 functional food 2
There were 30 tablets.

【0011】実施例2としては、上記の機能性食品1に
対して、キチン及び/又はキトサンとして亜細亜製薬株
式会社のベーターサンCゴールド(以下、機能性食品3
という)を配合して、実施例2に係る機能性食品を得
た。機能性食品3は、顆粒状をなしたものを個袋に包装
したものであり、その成分はキトサン300mg、キチン
オリゴ糖300mg、ベータカロチン5mg、ビタミンC4
0mg、クロレラ30mg、ゼラチン20mg、シイタケエキ
ス30mgである。配合に際しては、機能性食品3を機能
性食品1に配合して攪拌した。配合比率は、1本の機能
性食品1に対して、機能性食品3を1〜5包とした。
Example 2 is the same as the functional food 1 described above, except that chitin and / or chitosan is Beta Sun C Gold (hereinafter referred to as functional food 3) manufactured by Asia Pharmaceutical Co., Ltd.
Was added to obtain the functional food according to Example 2. The functional food 3 is a granular product packaged in individual bags, and the components thereof are chitosan 300 mg, chitin oligosaccharide 300 mg, beta carotene 5 mg, and vitamin C4.
It is 0 mg, 30 mg of chlorella, 20 mg of gelatin, and 30 mg of shiitake extract. At the time of compounding, the functional food 3 was mixed with the functional food 1 and stirred. The mixing ratio was 1 to 5 functional foods 3 per one functional food 1.

【0012】尚、キチン及び/又はキトサンとしては、
亜細亜製薬株式会社より、液状のベーターサンピュアー
ドリンクも市販されており、機能性食品1と混合するこ
ともできる。また、上記の配合量を適宜変更することも
可能であると共に、これらの機能性食品を複数配合する
ことも可能である。さらに、市販の機能性食品を用いず
に、実施することも可能である。
As chitin and / or chitosan,
Liquid beta-san pure drink is also commercially available from Asia Pharmaceutical Co., Ltd. and can be mixed with the functional food 1. In addition, it is possible to appropriately change the above-mentioned blending amount, and it is also possible to blend a plurality of these functional foods. Furthermore, it is also possible to carry out without using a commercially available functional food.

【0013】本願発明者は、数種の症例の知見に基づ
き、本願発明を完成させたもので、その症例1〜4を以
下に示す。
The inventor of the present invention has completed the present invention based on the findings of several types of cases, and cases 1 to 4 thereof will be shown below.

【0014】症例1 男性 61才(神戸市) 数年前より肝炎となり、表1
の如きγ−GTP等を値を示していた。種々の治療を受
け、食事療法も行ったが一進一退状態で、特に鼻の周辺
が赤黒く腫れ上がり脂肪が浮き出ていた。1993年6
月中旬より機能性食品1を1本/1日と、機能性食品2
を6錠/1日とを服用したところ、約1ケ月で回復し、
鼻の回りの腫れ等もなくなった。1993年7月中旬に
検査を受けた結果を表1に示す。
Case 1 Male, 61 years old (Kobe City) Hepatitis has been present for several years, and Table 1
Values of γ-GTP and the like were shown. After receiving various treatments and dieting, he was in a state of progress and withdrawal. Especially, around the nose was swollen red and black, and fat was exposed. 1993 6
From the middle of the month 1 functional food 1/1 day, functional food 2
, 6 tablets / day, recovered in about 1 month,
There was no swelling around the nose. Table 1 shows the results of the inspection conducted in the middle of July 1993.

【0015】[0015]

【表1】 GOT GPT γ−GTP 発病より数年間 100〜200 100〜200 200〜300以上 1993年7月 25 20 70[Table 1] GOT GPT γ-GTP Several years after the onset 100-200 100-200 200-300 or more July 1993 25 20 70

【0016】症例2 男性 63才(神戸市) 1991年より肝炎となり医
師による治療を受けていたが回復せず、1992年5月
にC型肝炎と診断され、インターフェロンの投与を勧め
られたが、副作用の心配より、漢方薬を服用して、小康
状態を保っていた。1993年8月より9月の約2ケ月
間、機能性食品1を1本/1日と、機能性食品2を4錠
/1日を服用したところ、急速に回復し、約2か月後の
同年10月始めの検査では、下記の表2に示す通りの結
果を得た。
Case 2 Male, 63 years old (Kobe City) He had hepatitis since 1991 and had been treated by a doctor but did not recover. He was diagnosed with hepatitis C in May 1992 and was advised to administer interferon. Rather than worrying about side effects, she took herbal medicine and was in a lull state. About 1 month / day of functional food 1 and 4 tablets / day of functional food 2 for about 2 months from August 1993 to September, and it recovered rapidly, about 2 months later. In the inspection conducted in October of the same year, the results shown in Table 2 below were obtained.

【0017】[0017]

【表2】 GOT GPT γ−GTP 1991年(肝炎発病時) 120 100 200 1992年5月(C型肝炎と診断時)125 135 220 1993年4月(漢方療法時) 70 120 100 1993年10月 23 18 52 1993年11月 25 17 63[Table 2] GOT GPT γ-GTP 1991 (when hepatitis develops) 120 100 200 May 1992 (when hepatitis C is diagnosed) 125 135 220 220 April 1993 (when Kampo therapy) 70 120 100 October 1993 23 18 52 November 1993 25 17 63

【0018】症例3 女性 55才(奈良市) 1991年よりC型肝炎とな
り入退院を繰り返していたが、さらに悪化し、1993
年8月にインターフェロンの投与を勧められた。副作用
の心配のため治療を断り、他の医師の診断を受けたとこ
ろ、外観(顔の血管の状況)より判断して、肝臓癌の恐
れもあるため、即時入院するように勧められたが入院せ
ず、1993年8月26日より機能性食品1を1本/1
日、機能性食品2を15〜30錠/1日、機能性食品3
を1包/1日を服用したところ、1週間目には元気が回
復し、2週間後の検査では良好な数値が示された。
Case 3 Female 55 years old (Nara city) He had been hepatitis C since 1991 and had been hospitalized repeatedly.
Administration of interferon was recommended in August 2012. He declined treatment because of concern about side effects and was diagnosed by another doctor, but was judged to be likely to have liver cancer based on his external appearance (face blood vessel condition). No, 1 functional food / 1 from 26 August 1993
15-30 tablets / day, functional food 2 / functional food 3
When 1 packet / day was taken, the patient recovered his vitality in the 1st week, and a good value was shown in the examination 2 weeks later.

【0019】[0019]

【表3】 GOT GPT γ−GTP 発病より2年間 90〜160 90〜100 100〜120 1993年9月9日 77 66 75[Table 3] 2 years after GOT GPT γ-GTP onset 90-160 90-100 100-120 September 9, 1993 77 66 75

【0020】症例4 女性(63才) C型肝炎から肝硬変で入院中で、口か
ら食事を採ることが困難な状態で1ケ月以上点滴を続け
ていたが、両腕の皮膚が破れて数カ所より出血し、その
都度、焼ゴテで止血する有り様で、医師より1ケ月の余
命であると告げられていた。1993年8月末より機能
性食品1を1本/1日と、機能性食品2を30錠/1日
(カプセル内よりペースト状体のみを取り出し、口内に
流し込む)とを服用したところ、1ケ月後には、担当の
医師によると肝機能の67%は回復しているとの事であ
り、実際にも車椅子で病院内を移動できる状態にまでな
った。
Case 4 Female (63 years old) Hepatitis C was admitted to the hospital for cirrhosis, and he continued to drip for more than 1 month in a state where it was difficult to take food from the mouth, but the skin of both arms was torn, and from several places. He was bleeding, and each time he was bleeding with a roasting iron, he was told by his doctor that he had one month to live. From the end of August 1993, take 1 functional food / 1 day and 30 functional foods / 1 day (take only paste from capsule and pour into mouth) for 1 month. Later, according to the doctor in charge, 67% of the liver function had recovered, and he was actually able to move around the hospital with a wheelchair.

【0021】以上の4例は、何れもC型肝炎、肝硬変
(末期)、アルコール性脂肪肝等の重症患者が、1〜3
ケ月で回復したものであり、キチン・キトサンについて
の講演会等の症例として紹介されている例では回復まで
に3〜6ケ月を要しているのに比して、極めて早い回復
状況であると考えられるものであり、本願発明者は、か
かる回復状況に基づき、本願発明を完成させたものであ
る。
In all of the above four cases, 1 to 3 are severe patients with hepatitis C, cirrhosis (end stage), alcoholic fatty liver, etc.
It was recovered in a month, and the case introduced as a case at a lecture meeting on chitin and chitosan required 3 to 6 months to recover, which is an extremely early recovery situation. The present inventor has completed the present invention based on such a recovery situation.

【0022】[0022]

【発明の効果】本願発明は、甘草の抽出物の肝障害保護
作用等の薬理作用をさらに向上させ、C型肝炎に関して
も保健予防効果及び保健治療効果を発揮することのでき
る機能性食品用組成物を提供することができたものであ
る。
INDUSTRIAL APPLICABILITY The present invention further enhances the pharmacological action of licorice extract such as the action for protecting liver damage and the like, and is a functional food composition capable of exerting a preventive effect on health and a therapeutic effect on hepatitis C. I was able to provide things.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 甘草属植物から得られる抽出物と甘草属
植物から得られる抽出物の乳酸醗酵物とから選択される
少なくとも一種と、キチンとキトサンとから選択される
少なくとも一種とを配合してなる機能性食品用組成物。
1. A blend of at least one selected from an extract obtained from a licorice plant and a lactic acid fermentation product of an extract obtained from a licorice plant, and at least one selected from chitin and chitosan. Functional food composition.
JP5314499A 1993-11-19 1993-11-19 Composition for functional food Pending JPH07135923A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5314499A JPH07135923A (en) 1993-11-19 1993-11-19 Composition for functional food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5314499A JPH07135923A (en) 1993-11-19 1993-11-19 Composition for functional food

Publications (1)

Publication Number Publication Date
JPH07135923A true JPH07135923A (en) 1995-05-30

Family

ID=18054034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5314499A Pending JPH07135923A (en) 1993-11-19 1993-11-19 Composition for functional food

Country Status (1)

Country Link
JP (1) JPH07135923A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1070A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Processed food useful for beauty and health
CN1067531C (en) * 1997-01-13 2001-06-27 陈乐玫 Health-care chitosan-chitin food
JP2001316271A (en) * 2000-05-01 2001-11-13 Kobayashi Pharmaceut Co Ltd Chitosan containing composition
JP2003026592A (en) * 2001-07-09 2003-01-29 Nippon Hypox Lab Inc Anti-androgenic agent comprising fermented licorice extract
JP2008189655A (en) * 2006-11-26 2008-08-21 Ahmed Mohamed Ali Massoud Dr Medicament for treating complication of true diabetes mellitus
CN100434075C (en) * 2006-12-05 2008-11-19 中国人民解放军军事医学科学院生物工程研究所 Usage of caffeine and its analogue in resistance of hepatitis B replication and use thereof in preparation of medicament for treating viral hepatitis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1070A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Processed food useful for beauty and health
CN1067531C (en) * 1997-01-13 2001-06-27 陈乐玫 Health-care chitosan-chitin food
JP2001316271A (en) * 2000-05-01 2001-11-13 Kobayashi Pharmaceut Co Ltd Chitosan containing composition
JP2003026592A (en) * 2001-07-09 2003-01-29 Nippon Hypox Lab Inc Anti-androgenic agent comprising fermented licorice extract
JP2008189655A (en) * 2006-11-26 2008-08-21 Ahmed Mohamed Ali Massoud Dr Medicament for treating complication of true diabetes mellitus
CN100434075C (en) * 2006-12-05 2008-11-19 中国人民解放军军事医学科学院生物工程研究所 Usage of caffeine and its analogue in resistance of hepatitis B replication and use thereof in preparation of medicament for treating viral hepatitis

Similar Documents

Publication Publication Date Title
AU725308B2 (en) Anti-stress composition
CN106962912A (en) A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof
CN107319525A (en) One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof
DE2621000A1 (en) NUTRITIONAL DEFICIENCY PREVENTION COMPOSITION
JP2002179586A (en) Lipase inhibitor
CN104839688A (en) Eye care preparation and preparation method thereof
CN107616490A (en) A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof
CN106858595A (en) One kind burn tailored version clinical nutrition formula and preparation method thereof
US8722614B2 (en) Adiponectin production enhancer
JP6463504B2 (en) Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement
TW201943417A (en) Food composition for cognitive function improvement, cognitive function improving agent, and production method thereof characterized by containing L-ergothioneine as an active ingredient
KR20020092082A (en) Tonic composition
CN112674351A (en) Composition for improving cognitive function speed
KR100699782B1 (en) Food composition for improving liver function comprising a Lonicera caerulea L. var. edulis extract
JPH07135923A (en) Composition for functional food
JP4988085B2 (en) Liver function activator
JP4053686B2 (en) Bioactive health food
KR102439576B1 (en) Composition of Nutrient Delivery System for Improving Brain Function
JP2004189619A (en) Nourishing tonic medicine
KR20140106058A (en) Composition for enhancing immunological activity comprising soluble salmon milt extract and vegetable lactic acid bacteria
JP7104267B1 (en) Cognitive function improver
JP2009084191A (en) Pharmaceutical composition for inhibiting appetite
JP4610730B2 (en) Composition for calcium supplementation
CN104738700A (en) Liver-protecting loach product and preparation method thereof
CN106659707B (en) Erythrocyte function-improving agent